Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations
- 27 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (6) , 988-993
Abstract
Background and Aims: Some patients with ulcerative colitis [UC] do not respond to vedolizumab treatment despite adequate drug exposure in serum. This study aimed to investigate vedolizumab in tissue and questioned whether insufficient tissue exposure could explain non-response in UC patients with adequate serum vedolizumab concentrations.Methods: A paired serum sample and colonic mucosal biopsy was collected from 40 UC patients [20 endoscopic responders, 20 non-responders] at week 14 of vedolizumab treatment. Vedolizumab, soluble [s]-mucosal addressin cell adhesion molecule-1 [MAdCAM-1], s-vascular cell adhesion molecule-1 [VCAM-1] and s-intercellular adhesion molecule-1 [ICAM-1] were measured in serum and/or tissue. Endoscopic response was defined as Mayo endoscopic sub-score ≤1.Results: A significant positive correlation was observed between vedolizumab serum and colonic tissue concentrations [ρ = 0.84, p < 0.0001], regardless of the macroscopic inflammatory state of the tissue. Vedolizumab tissue concentrations were lower in non-responders than in responders [0.07 vs 0.11 µg/mg, p = 0.04]. In the subgroup of patients with adequate vedolizumab serum concentrations [>14.6 µg/mL], tissue vedolizumab was not significantly different between responders and non-responders [0.15 vs 0.13 µg/mg; p = 0.92]. Serum sMAdCAM-1 concentrations, but not serum sICAM-1 or sVCAM-1 concentrations, were significantly higher in responders than in non-responders with adequate vedolizumab serum concentrations [1.04 vs 0.83 ng/mL, p = 0.03].Conclusions: Vedolizumab concentrations in colonic mucosal tissue of UC patients reflect the concentration in serum regardless of the macroscopic inflammatory state of the tissue. Our data show that insufficient tissue exposure does not explain non-response in UC patients with adequate serum vedolizumab concentrations.Keywords
Funding Information
- Research Foundation—Flanders
This publication has 26 references indexed in Scilit:
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment FailedGastroenterology, 2014
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- Value of drug level testing and antibody assays in optimising biological therapyFrontline Gastroenterology, 2012
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel DiseasesThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitisNature Clinical Practice Gastroenterology & Hepatology, 2006
- Bioassay detects soluble MAdCAM‐1 in body fluidsImmunology & Cell Biology, 2004
- Increased expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and lymphocyte recruitment in murine gastritis induced byHelicobacter pyloriClinical and Experimental Immunology, 2002
- Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in ratsClinical and Experimental Immunology, 2001
- Circulating soluble adhesion molecules in inflammatory bowel diseaseEuropean Journal of Gastroenterology & Hepatology, 1995